May 06, 2021
U.S. Compounding Inc. and its parent Adamis Pharmaceuticals Corp. have agreed to pay $7.9 million as part of a deal to end a lawsuit by Nephron Pharmaceuticals Corp. claiming they stole its trade secrets through a former employee.
March 03, 2021
A Florida federal court has held U.S. Compounding Inc. and its parent, Adamis Pharmaceuticals Corp., in civil contempt for violating an injunction regarding trade secrets that Nephron Pharmaceuticals Corp. claims they misappropriated through two of its former employees, saying the injunction was clear and unambiguous and covers the alleged violations.